Decision: Favourable

Study Title:

A 52-week, randomised, double-blind, placebo-controlled, parallel group, multi-centre study of the efficacy and safety of GSK3511294 adjunctive therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype

  • NREC Code:

    21-NREC-CT-171

  • Decision:

    Favourable

  • Meeting Date:

    08/12/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Desmond Michael Murphy

  • PI Institution:

    Cork University Hospital

  • Sponsor:

    IQVIA on behalf of GlaxoSmithKline Research & Development Limited

Scroll to Top